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margin = 2.25mm (Range 1.25-3mm). Median PTV volume = 32cc 
(Range= 6-1879cc).Prescription dose was 30-36Gy in 3-5# (BED using 
α/β=10, 48-79). Dose was prescribed to the Median 64% isodose line 
(Range 48-78%). Median coverage was 98.3% (range 95.2-99.9%). 
Treatment delivery was tracked with fiducials and the Synchrony 
system. 
Results: Outcome data was available for 10 patients. Local Control 
rate was 100%. 4 patients (40%) progressed distantly, 2 in the IMC 
Node group, and 2 in the Sternum group. One of the patients that 
progressed distantly in the Sternal group had distant disease at the 
time of CyberKnife. Of those that progressed distantly, 75% had 
received chemotherapy as their first treatment at the time of 
Sternal/IMC node recurrence. Median Disease-Free Interval (DFI) in 
progressors was 2 years (Range 1-6 yrs), compared to a DFI in Non-
progressors of 3 years (Range 1-13 yrs). Median Progression-Free 
Survival for the IMC node group, Sternal group, and Cohort as a whole 
were 6, 2 and 4 months respectively. The follow-up data was, 
however, less mature for the Sternal group. Overall Survival (OS) rate 
was 90%. The patient that died was had Sternal recurrence patient 
with small lung metastases at the time of CyberKnife treatment. She 
died of lepto-meningeal disease. Median OS for IMC node group, 
Sternal group and Cohort as a whole were 16, 2 and 6 months 
respectively. However, follow-up data is less mature for the Sternal 
group. Treatment was well tolerated with only 25% of the group 
experiencing acute toxicity (G1). Only 1 patient experienced Late 
toxicity (fleeting G3 symptoms), the patient had received prior 
rdaiotherapy. 
Conclusions: SBRT is a feasible treatment approach for patients with 
Sternal/IMC nodal recurrence of Breast Cancer. The technique is well 
tolerated, even in those who have received prior Radiotherapy. The 
outcome data is still immature, but the early Local Control rates 
(100%), and Overall Survival rates (90%) at a Median follow-up of 11 
months are encouraging.  
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Purpose/Objective: The management of disease recurrence within a 
previously irradiated pelvic field is a challenging clinical problem. The 
ability to re-irradiate the pelvis to a therapeutically meaningful dose 
is limited by the cumulative dose received by adjacent pelvic organs 
at risk (OAR). The Cyberknife radiosurgery system enables highly 
conformal dosimetry with rapid dose fall off outside of the target. 
This, in combination with the use of small treatment margins 
facilitated by tumour tracking, make it a potentially attractive 
delivery platform for re-irradiation. 
The aim of this retrospective study was to review the toxicity and 
early efficacy data of patients receiving SBRT with the Cyberknife 
platform for pelvic re-irradiation at our institution. 
Materials and Methods: Patients receiving Cyberknife SBRT to 
abdominopelvic targets sited within a previously irradiated field were 
retrospectively identified. Details on primary site histology, prior 
external beam radiotherapy (EBRT), re-irradiation dose and indication 
for re-treatment were obtained from the patient’s electronic notes. 
Radiotherapy toxicity was graded using CTCAE v4.0. Follow up 
consisted of clinical examination and radiological assessment. In field 
local control and time to progression were calculated from the day of 
completing SBRT until the date of radiological evidence of progression 
using standard RECIST criteria. 
Results: 16 patients were treated between 01.08.11-01.11.12. Median 
follow up was 6 months (range 1-15). 8 patients had primary 
gynaecological malignancies, 7 colorectal and 1 melanoma. Median 
age was 59 years (range 27-85). Indications for re-irradiation were 
nodal recurrence (6), soft tissue recurrence (7) and positive margins 
following surgery (3). Median time from previous EBRT was 20 months 
(range 1-156). Median previous EBRT dose was 50.4 Gy (range 30-54) 
in 28 fractions (range 10-39). 3 patients with gynaecological primaries 
had also received prior brachytherapy. Median re-irradiation dose was 
30 Gy (range 18-35) in 3 fractions. 44% of patients had no recordable 
toxicity. 3 patients with pelvic side wall recurrences experienced G2 
pain during treatment, which resolved shortly after completion of 
SBRT. One patient developed a colovesical fistula 2 months after SBRT 
(G4 toxicity). This was associated with local disease recurrence 
therefore the aetiology was unclear. At last follow up, local control is 
94% (15/16 patients). A single patient had an in field recurrence 2 
months after SBRT. 6/16 patients (38%) have relapsed at distant sites. 
Median time to relapse at any site was 3 months (range 2-11). 
Conclusions: At this early time point of data analysis, minimal toxicity 
has been observed to date. Cyberknife SBRT is a promising method for 
pelvic re-irradiation and warrants further investigation.  
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Purpose/Objective: The use of autosegmentation computed systems 
in clinical setting for locally advanced rectal cancer is time sparing 
with an acceptable Dice Coefficient for CTV, Mean Dice Coefficient 
(MDC) of 0.70, while it does not reach an adequate value for small 
nodal subvolumes (MDC=0.67) (1). In this phase II study the objective is 
to verify in clinical setting the time sparing and the Dice Coefficient in 
bigger volumes (CTV and grouped nodal subvolumes) in locally 
advanced rectal cancer using the Smart Segmentation Knowledge 
Based Contouring (SS-KBC)® research program.  
(1) Clinical validation of atlas-based auto-segmentation of pelvic 
volumes and normal tissue in rectal tumors using autosegmentation 
computed system. Gambacorta et al, Acta Oncologica, in press 
Materials and Methods: 29 consecutive patients were selected 
between June and September 2012; images of 14 patients as atlas, 15 
for validation. To test the reliability of the system for bigger volumes, 
the nodal subvolumes were grouped according to clinical stage and 
site of the tumor (tab1). According to our ongoing QA program two 
operators were involved: a Delineator and a Reviewer. CTV and pelvic 
grouped nodal subsites were contoured by Delineator in 2 different 
sequences (A-manual vs B-autosegmentation) of contouring using the 
same planning CT; all of them underwent to Indipendent Check by 
Reviewer. To improve the reliability of the system many 
anthropometric characteristics where analyzed (including BMI, sex, 
age, fertility state, sacro-coccigeal distance and the most anterior 
distance between upper iliac crests). The analysis was conducted to 
test the reliability of the system using Dice Coefficient and the total 
time spared by the Delineator to complete the 2 different sequences. 
 
 
Results: In clinical practice the time spared by operator 1 to complete 
sequence A and B was of 14min vs 1min respectively; there was a 
statistically significant better MDC in favor of sequence A vs sequence 
B: 
-CTV: sequence A (MDC=0.86) vs sequence B (MDC=0.78), p=0.001 
(fig.1) 
-Subvolume 1: sequence A (MDC=0.86) vs sequence B (MDC=0.77), 
p=0.001 
-Subvolume 2a: sequence A (MDC=0.76) vs sequence B (MDC=0.66), 
p=0.001 
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Conclusions: This analysis showed a MDC with a statistically 
significant advantage in favor of sequence A for both CTV and nodal 
subvolumes. Nevertheless, MDC in sequence B for CTV and subvolume 
1 were close to 0.80 and therefore clinically reliable, with a time 
sparing of 93%. Final analysis will confirm the clinical reliability and 
feasibility of the system and the total time sparing for both the 
Delineator and the Reviewer. 
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Purpose/Objective: Positron emission tomography (PET) with [18F]-
fluoromisonidazole (FMISO), a tracer of hypoxia, is particularly useful 
in radiotherapy with potential dose escalation on hypoxic subvolumes. 
However, the definition of FMISO volumes remains problematic due to 
the low contrast of the images and the absence of consensus about 
the segmentation methods.  
Materials and Methods: The aim of this methodological study about 
the use of FMISO PET for radiotherapy planning is to determine the 
best timing for acquisitions and to study different volume 
segmentation methods. For this purpose, 15 patients with head and 
neck suamous cell carcinomas (HNSCC) underwent FMISO-
PET/Computed tomography (CT) with several acquisitions at 2, 3 and 
4 hours after injection of the tracer and three different automatic 
segmentation methods of PET volumes were tested. The first method 
was a fixed thresholding, the FMISO volume being defined by all voxels 
having an activity ≥ 1.4 of the activity of the background (AB). The 
second method was an adaptive thresholding based on the ratio 
between the maximum tumour activity (AT) and AB (RT/B). The third 
method was a stochastic algorithm, the fuzzy locally adaptive 
Bayesian (FLAB) method. Tumour volumes were also manually 
delineated on the CT images by the radiation oncologist. 
Results: For one patient, no hypoxia was observed. For eight patients, 
hypoxia was observed in the primary tumour and nodes, for two in the 
primary tumour only and for four in the nodes only. The calculated 
mean RT/B was 2.5 (range 1.7-2.9), 3.1 (range 2-4.5) and 3.4 (range 
2.3-6.1) for images aqcuired at 2, 3 and 4 hours respectively. It 
appears that the best contrast is obtained on the 4 hour-acquisition. 
At 4 hours, the mean FMISO volumes were 18.9 cc (range 0.1-81) with 
the fixed threshold, 9.5 cc (range 0.9-33.1) with the adaptive 
threshold and 12.5 cc (range 0.9-38.4) with the FLAB method. The 
volumes defined with the adaptive threshold were also the smallest. 
The fixed threshold led to larger volumes (199% of the adaptive 
volumes) and the FLAB volumes were intermediate (132% of the 
adaptive volumes). CT volumes were much larger with a mean of 39.1 
cc (range 1.2-116) corresponding to a value more than 4 times larger 
than the FMISO adaptive volume.  
Conclusions: Compared to CT imaging, FMISO PET imaging in HNSCC 
enables to define restricted volumes, on which a potential increase of 
the radiation dose is possible. For a radiotherapy application, images 
must be acquired 4 hours after injection to provide a better contrast. 
Adaptive or stochastic methods are more appropriate to FMISO volume 
segmentation. Indeed, FMISO images are low contrasted and fixed 
thresholding leads to overestimated volumes. However, because of 
the lack of published data, additional work is required before using 
FMISO PET to guide dose painting in intensity modulated radiotherapy. 
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Purpose/Objective: SBRT is increasingly considered an alternative to 
surgical resection of liver metastasis or liver related cancers. Our 
clinical workflow consists of precise target localization; analysis of 
tumor motion due to respiration; highly conformal dose distribution; 
and image-guidance at the time of dose delivery. Tumor and normal 
tissue reponse is monitored through morphological changes by MRI. 
Quantitative in vivo data of the hepatic tolerance to irradiation is very 
limited. However, such knowledge is essential for the treatment 
strategy in patients with multiple or large tumors or in situations with 
a small parenchymal reserve after liver resection. In a feasibility study 
for further healthy liver sparing, four consecutive patients with liver 
lesions were retrospectively evaluated. 
Materials and Methods: Clincal cases consist of (1) solitary 
metastases/breast cancer; (2) four metastases/cholangiocellular 
carcinoma; (3) R1-resected gallbladder cancer; (4) multiple 
metastasis/bladder cancer. For all patients a 4D-CT scan was 
performed. GTV contours of the single calculated respiratory phases 
(10 in total) were transfered to the average CT of the 4D-CT data to 
generate the ITV. Highly conformal dose coverage was achieved by 
Varian VMAT using 6 MV photons. Dose prescription ranged from 5 x 7 
Gy (60% isodose surrounding the PTV) to 25 x 1.8 Gy (ICRU). MRI was 
carried out before and 6 weeks/3 month after therapy. MR-sequences 
were conducted with T1-w GRE enhanced by hepatocyte-targeted Gd-
EOB-DTPA. MRI data sets were merged with the planning CT including 
the dose distribution. Reviewers indicated the border of hypointensity 
on T1-w images (loss of hepatocyte function) or hyperintensity on T2-
w images (edema). The potential of healthy liver sparing was 
estimated by the treshold dose for these morphological changes. 
Results: Analysis of the 4D-CT data resulted in a mean target motion 
from 5 to 9 mm in magnitude. Kilo-voltage CBCT scans were created 
before each fraction to verify and adjust the target localization. 
Image fusion of the average treatment planning CT and kV-CBCT scans 
resulted in patient repositioning in a maximum of 6 mm magnitude 
per fraction. The dose to the liver was within accepted guidelines 
(700 ml healthy liver receiving less than 15 Gy). The minimum dose 
resulting in visible signal intensity changes (edema/loss of hepatocyte 
function) was approximately 20 Gy (Fig. 1). Depending on the number, 
size and location of the metastases and the healthy liver volume, the 
remaining healthy volume (excluding the 20 Gy liver subvolume) 
measures from 10 to 40%. 
 
  
Conclusions: In SBRT of liver metastases, 4D-CT data is required for 
target motion management and treatment planning. In this 
preliminary retrospective evaluation, a threshold dose of 
approximately 20 Gy inducing focal loss of liver function was detected 
after 4 weeks by MRI. Further investigation is warranted to assess the 
correlation between morphological changes in the mean dose 
exposure to the liver and clinical outcome.  
  
